低分子肝素钙对COPD合并肺心病患者心肺功能、BNP及炎症因子水平的影响

doi:10.3969/j.issn.1671-7171.2019.06.023

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effects of low molecular weight heparin calcium on cardiopulmonary function, BNP (brain natriuretic peptide) levels and inflammatory status in patients with COPD (chronic obstructive pulmonary disease) complicated with pulmonary heart disease. 【Methods】A total of 97 patients with COPD complicated with pulmonary heart disease who were treated in our hospital from March 2016 to March 2018 were randomly divided into the observation group (49 cases) and the control group (48 cases). The control group was treated with conventional treatment measures, and the observation group was treated with low molecular weight heparin on the basis of the control group. One week after treatment, the changes of coagulation function, lung function and blood gas index before and after treatment were observed. The BNP levels and inflammatory status of the two groups were analyzed before and after treatment. 【Results】The prothrombin time (PT), activated partial thromboplastin time (APTT), blood oxygen saturation (SpO₂), arterial oxygen partial pressure (PaO₂), one second forced expiratory volume (FEV1), the first-second forced expiratory volume occupancy capacity (FEV1/FVC) and one second rate (FEV1%) in the observation group were significantly higher than the control group. The D-dimer (DD) content and arterial blood carbon dioxide partial pressure were significantly lower than the control group; the difference between the two groups was statistically significant (P<0.05). Brain natriuretic peptide (BNP), interleukin 6 ( The levels of IL-6), tumor necrosis factor (TNF-α) and high-sensitivity C-reactive protein (hs-CRP) in the observation group were significantly lower than the control group, and the difference was statistically significant (P<0.05). 【Conclusion】Low molecular weight heparin calcium in patients with COPD complicated with pulmonary heart disease can improve cardiopulmonary function and reduce BNP levels and inflammatory response in patients.

Key words： Pulmonary Disease, Chronic Obstructive/CO Pulmonary Heart Disease/DT Pharmaceutical Preparations

Received: 15 March 2019

PACS:

R563

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2019.06.023 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2019/V36/I6/1109

[1] 肖建,杜春玲.慢性阻塞性肺疾病病因及发病机制研究进展[J].中国老年学杂志,2014,34(11):3191-3194.
[2] 李玉群,梁贤球,何晟,等.稳定期COPD患者营养状况与血清脂联素、肺功能、CAT评分的关系[J].安徽医科大学学报,2014,49(7):969-972.
[3] 孙哲琳,陈重军,杨令延,等.PM_(2.5)水溶性和有机组分对肺上皮细胞损伤及COPD相关基因和蛋白表达影响[J].环境科学学报,2016,36(11):4262-4271.
[4] 梁兵鑫,胡三保.低分子肝素钙联合气压式血液循环驱动器防治老年骨折患者术后下肢深静脉血栓的临床观察[J].中国药房,2015,26(35):4989-4991.
[5] 邵海燕,陈君峰.西地那非联合低分子肝素钙治疗慢性阻塞性肺病合并肺心病的疗效观察[J].中国现代医生,2014,52(16):146-148.
[6] 唐文芳,刘日辉,于雅琴,等.2000—2014年中国40岁以上成人慢性阻塞性肺疾病患病率的Meta分析[J].吉林大学学报(医学版),2015,41(5):961-968.
[7] 兰丰铃,王胜锋,曹卫华,等.慢性阻塞性肺疾病危险因素流行病学研究新进展[J].中华疾病控制杂志,2014,18(10):998-1002.
[8] 贺其根.慢性阻塞性肺病合并肺原性心脏病急性加重期治疗前后血浆脑利钠肽测定的临床意义[J].中国现代医学杂志,2014,24(34):34-37.
[9] 陈玉玲,顾翔,孙思,等.Nogo-B在慢性阻塞性肺病合并肺心病中的变化及意义[J].实用医学杂志,2015,31(3):378-380.
[10] 刘静华.低分子肝素钙皮下注射治疗慢性阻塞性肺疾病急性加重期合并肺心病疗效观察[J].山东医药,2014,54(32):40-42.
[11] 徐莉,杨永青,赵香莲.血清HDL-C、TNF-α检测在COPD急性加重期治疗中的应用[J].山东医药,2015,55(29):69-71.
[12] 胡绘,赵苏,孔德勇,等.联合检测hs-CRP、PCT和BNP在COPD急性恶化期中的诊断价值[J].重庆医学,2015,44(35):5010-5012.
[13] 万兵飞,肖思科.超敏C反应蛋白检测在慢性阻塞性肺疾病急性加重期的临床意义[J].湖南师范大学学报(医学版),2009,6(4):55-56.
[14] 王斌,陈国强,李琳瑕,等.炎性生物标志物对COPD患者死亡的影响[J].湖南师范大学学报(医学版),2015,12(4):9-11.
[15] 傅振会,任波,赵群都.低分子肝素钙预防ICU患者静脉血栓栓塞症的临床观察[J].中国药房,2016,27(20):2838-2841.
[16] 丁明霞,卢丹,常媛媛,等.低分子肝素治疗老年慢性阻塞性肺疾病合并肺心病急性发作期效果[J].临床肺科杂志,2015,20(3):487-489.